Valneva Secures $32.8 Million Contract for IXIARO Vaccine Supply

Valneva Expands IXIARO Vaccine Supply with New Contract

Valneva SE, a leading specialized vaccine company, has officially announced a significant step forward in its partnership with the U.S. Department of Defense (DoD) by signing a new contract valued at a minimum of $32.8 million for the IXIARO vaccine. This substantial agreement marks another chapter in Valneva's commitment to protecting public health through effective vaccination against infectious diseases, specifically Japanese encephalitis (JE).

Strengthening Relationships with the U.S. Military

Dipal Patel, the Chief Commercial Officer of Valneva, expressed pride in the long-standing relationship between Valneva and the DoD. He noted that for over ten years, the U.S. military has relied on IXIARO to safeguard the health of personnel, their families, and government contractors against the severe impacts of Japanese encephalitis. This mutual trust underscores the efficacy of IXIARO and its critical role in military health strategies.

Understanding IXIARO and Its Impact

IXIARO is notably the only Japanese encephalitis vaccine that holds approval from the U.S. Food and Drug Administration (FDA). Its development stemmed from a collaborative research agreement with the esteemed Walter Reed Army Institute of Research, reflecting the vaccine's strong scientific foundation. Valneva directly markets IXIARO to military personnel and the private travel market across the U.S., further expanding its impact and accessibility.

About the Japanese Encephalitis Vaccine

This specialized vaccine is crucial for individuals traveling to or residing in areas where JE is endemic. IXIARO has gained widespread recognition, receiving marketing approval in several regions, including the U.S., Europe, and various countries across Asia and the Pacific regions, under different trade names. Valneva ensures that IXIARO is available for individuals from two months of age, making it an essential health option for families and travelers.

Japanese Encephalitis: A Global Health Concern

Japanese encephalitis remains a formidable health threat, particularly in Asia, where the disease claims thousands of lives annually. It is responsible for approximately 70,000 cases each year, with a high mortality rate. Many affected develop severe neurological complications leading to permanent disabilities. Consequently, enhancing vaccine access and awareness is vital in combating this disease.

Valneva's Broader Mission and Future Goals

Valneva's mission extends beyond the IXIARO vaccine. The company focuses on developing and commercializing vaccines for infectious diseases where there is an unmet medical need. Their innovative approach and expertise allow for the advancement of multiple vaccine candidates, including one for Lyme disease in partnership with Pfizer, alongside promising candidates for the Zika virus and other public health threats.

Building on Success and Innovation

Through robust revenues from its commercial operations, Valneva continues to invest in research and development efforts, striving to introduce first-, best-, or only-in-class vaccine solutions. This commitment is central to their strategy as they work to expand vaccine access globally, supporting initiatives to prevent infectious diseases.

Frequently Asked Questions

What is the new contract announcement about?

Valneva announced a new contract worth $32.8 million with the U.S. DoD for the supply of IXIARO, a vaccine for Japanese encephalitis.

How long is the contract for IXIARO?

The contract is a one-year agreement with the possibility for additional doses to be purchased over the next twelve months.

What is IXIARO used for?

IXIARO is a vaccine that protects against Japanese encephalitis, a serious infectious disease, particularly for travelers to endemic areas.

Who developed IXIARO?

IXIARO was developed through a cooperative research agreement with the Walter Reed Army Institute of Research and is manufactured by Valneva SE.

Where can IXIARO be accessed?

IXIARO is available in various regions, including the U.S. and Europe, and is marketed directly to military personnel and travelers.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.